^
Association details:
| Biomarker: | FLT3-ITD mutation |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | Koselugo (selumetinib) (MEK inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Phase II Study of the Oral Mek Inhibitor Selumetinib in Advanced Acute Myeloid Leukemia (AML): A University of Chicago Phase II Consortium Trial
Excerpt:
Forty-seven patients with relapsed/refractory AML or ≥60 years old with untreated AML were enrolled on a phase II study. Patients were stratified by FLT3 ITD mutation status….No patient with FLT3 ITD responded….
DOI:
https://dx.doi.org/10.1158%2F1078-0432.CCR-13-1311
